Member Info for Nixynoo

Looking at the level 2 data, It could still fall back to around 18p - there is a lot of support at 17.85 - 18p....

Majority of the small trades are marked automatic....

https://www.lstmed.ac.uk/news-events/news/lstm-researchers-find-an-easy-alternative-to-nasal-and-throat-swabbing-for-sars-cov

Result well worth a read....

Dave b 1, If you look back to May time when the Medusa tie up was announced, you will see that a lot of people questioned at this point why Avacta would tie up with a clothing distributor. It is best for you spend 30 minutes or so reading up on this and making up your own mind on whether it was a shrewd decision or not! The fact that the agreement is only direct to consumer and allowed for Avacta to negotiate with governments etc is the key point as far as I am concerned. Avacta don’t want to be dealing with lots of small scale purchases - Boohoo have the experience and infrastructure to deal with these transactions. Avacta are in complete control of negotiations with governments and those will most likely dwarf any with the consumer market. Furthermore, they won’t have to invest in a distribution channel and associated accounting team to be able to deal with the 3-4 major customers that they will be dealing with.

Besides, you should be very comfortable with your investment as the current SP is pretty well supported without the successful launch of the COVID LFT - even the recent extension of contract with Daewoong contains enough upfront cash, milestone payments and demonstrable success in early assessment of affimers. I’m looking forward to the interim results - hoping that they show the full extent of this extension which was pegged as being worth £1bn alone in recent coverage.

I believe that it is very cheap compared to the value in the remaining underlying business. Now that they have cut free the loss making divisions, sorted financing, have stronger board in place, they can focus on growing the innovative parts of their business. Throw in the fact that they are likely to benefit from the need for precision plastic medical tooling and I believe a price target of 25-30p in the short term (re rate) and potentially even more once the extent of any new business is fully understood.

I was alerted to the existence of this share via Avacta - once I looked into the financials and did a bit of research into the company it seemed like a no brainier to invest as the company appears to be significantly undervalued right now without even considering the potential from the medical supply division. Sure the pension scheme deficit it a worry, but the refinancing and contribution payment schedule that has been put in place is reassuring on that front and the sale of loss making divisions is another positive. GLA DYOR

Wylie,

The pilot in Southampton was to test whether saliva was as reliable as nasal swab for diagnosing covid - there were a number of companies involved including Avacta - the testing in Salford that has just been announced is to establish whether mass testing via saliva of a whole population of people could better manage the spread of covid. Again it is a test of a process rather than of a specific company’s product.

If you read the primary bid offer details, it states that it is to cover working capital and allow the auditors to issue a clean going concern audit opinion (ie they need this money to be considered a going concern). It is therefore to cover fixed costs like salaries etc (50/50 w/c and an unnamed JV)....THe RNS also states that the primary bid offer needs to read in conjunction with the financial statements due to be issued later today.

Just for clarity - I have just checked and HL do not lend out stock, so there is no shorting occurring from shares held there

Because I bought on the spike! I thought they were going places!

I hold ODX - literally my worst performing share in my whole portfolio ever... its lost so much value it is not even worth bothering to sell it... pretty much guarantee that it will go down by 7-10% per day and on the one day it did go up in value there was a placement the next day! I hope it does come good, but seriously... not really in the same league as Awacta!

I’ve just received a news report through on stockopedia stating that trials of the saliva test are being piloted... can’t open it as I didn’t subscribe, but perhaps market is perceiving this as progress?

AS - thankfully you didn't bail out at 97p!!
I bailed out of GDR at £1 and that has now risen - silly me! It was between GDR and ODX as I felt too much Covid carrying both of these and Avacta and I selected the wrong horse.. Double punishment with ODX announcing a placing today. Incidentally I was also eyeing up buying Novacyt at £2 on Monday when I sold out of GDR and decided it was too much of a risk and that hit £2.60 yesterday. I was also toying with buying more Avacta at 97p - again decided too much risk for me in one share at that point in time.

I think we all have plenty of tales to tale of losses that we have stupidly crystallised because of fear of losing out and profits missed out because the timing wasn't right when we purchased. Incidentally, I have only had 1 multi bagger in all of my years of trading on AIM - that was ABDP. My £5k punt eventually turned into a £122k but that was over 7 years and I have no idea how many times it went up and down in value as I paid very little attention to it over that time... I have had really solid returns from the likes of Amazon, Apple, Netflix, Ocado - all things that I use regularly - probably just shy of doubled my capital investment over that period of time in my whole portfolio. I do feel that Avacta could be up there with these companies in the future - hopefully Covid has put a spotlight on Affirmers for all the world to see and given the company an opportunity to propel the development of their various therapeutic and diagnostic opportunities. Anyway - Good luck to you - I hope that this turns good for you (and us all!)

There seems to be a distinct trend for transfer in food prep environments. Largest food market in Beijing, slaughterhouse in Frankfurt and now these two examples in Wales and Wrexham...

It is not just an independent verification! They have also tested its effectiveness on stopping the virus entering human cells. The previous RNS only confirmed the binding of the affirmer to the spike protein. You’ll fall off your spot in the ramping list at this rate PL!

Lost in space - I was just about to post the same thing. This is not just external scientific validation. It is the second stage of the validation that it would be an effective therapy in humans. Also reassuring that it has been completed by Glasgow Uni and not Tufts who have a vested interest in the technology.

Very exciting news indeed!

The moderator was particularly bad - thank goodness for Brendan...

The question has just been posed - Sona has answered that they are working with partners to develop into their tests. David didn’t get a chance to respond

Hi AdamStallone,

It is a very risky strategy to have all of your holdings in one company. I personally spread my portfolio over 68 companies in UK and US. Avacta is in my high risk pot - it is the amount that I can handle going to zero. My total holdings in my high risk pot are around 15% - 20%. I have 15% cash and the rest are in what I see as forever companies. In the US, it is FAAMG - I didn’t pick Netflix back up on the recent drop (silly me).

I hope that Avacta comes good for you (not least as I am heavily invested!) but please do try to put your eggs into more than one basket!

All the best,

Nix

https://www.labroots.com/webinar/panel-discussion-critical-design-considerations-covid-19-rapid-poc-diagnostic-test-development